Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Rs. 40 cr buyback, 200% dividend announced
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
The deal signals a clear push to expand access to care in underserved regions
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Subscribe To Our Newsletter & Stay Updated
